MONMOUTH JUNCTION, N.J.,
Aug. 30, 2012 /PRNewswire/
-- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical
company dedicated to the development of innovative inhaled
pharmaceuticals for the treatment of serious lung infections, today
announced that Timothy Whitten,
President and Chief Executive Officer, will be presenting a
corporate overview at the Stifel Nicolaus 2012 Healthcare
Conference in Boston on
Thursday, September 6, 2012, at
8:35 AM ET.
A live audio webcast will be made available on Insmed's website,
http://www.insmed.com. The webcast will also be archived for
30 days.
About Insmed
Insmed Incorporated is a biopharmaceutical company
dedicated to the development of innovative inhaled pharmaceuticals
for the treatment of serious lung infections, with a particular
focus on orphan diseases. Insmed's core expertise is the
development of inhaled antibiotic therapy delivered via proprietary
advanced liposomal pulmonary technology. For more
information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are
made pursuant to provisions of Section 21E of the Securities
Exchange Act of 1934. Investors are cautioned that such statements
in this release, including statements relating to our financial
position, our estimates regarding our capital requirements and our
needs for additional financing, our ability to access additional
funds under the Hercules loan agreement, results of operations, the
status, results and timing of results of pre-clinical studies and
clinical trials and pre-clinical and clinical data described
herein, the timing of and costs associated with pre-clinical
studies and clinical trials, the development of our products, our
estimates of the size of the potential markets for our product
candidates, and the business strategies, plans and objectives of
management, constitute forward-looking statements which involve
risks and uncertainties that could cause actual results to differ
materially from those anticipated by the forward-looking
statements. Our results may be affected by such factors as
the receipt and timing of U.S. Food and Drug Administration and
other regulatory reviews and approvals, if at all, competitive
developments affecting our product development, delays in product
development or clinical trials, and patent disputes involving
currently developing products. The risks and
uncertainties include, without limitation, we may experience
unexpected regulatory actions, delays or requests, our future
clinical trials may not be successful, we may be unsuccessful in
developing our product candidates or receiving necessary regulatory
approvals, we may experience delays in our product development or
clinical trials, our product candidates may not prove to be
commercially successful, our expenses may be higher than
anticipated, and other risks and challenges detailed in our filings
with the U.S. Securities and Exchange Commission, including our
Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on
Form 10-Q for the quarter ended June
30, 2012. Investors are cautioned not to place undue
reliance on any forward-looking statements which speak only as of
the date of this release. We undertake no obligation to
publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.com
Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com
SOURCE Insmed Incorporated